Datapoint: Lynparza Scores New Prostate Cancer Nod

The FDA on June 1 approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) in adult patients, in combination with Johnson & Johnson’s Zytiga and a corticosteroid. The new indication covers about 10% of mCRPC patients. Lynparza, a PARP inhibitor, was first approved in December 2014 for the treatment of advanced ovarian cancer. For this indication, it holds preferred status for 14.6% of all insured lives under the pharmacy benefit, growing to 47% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 6/5/23

0

0

0 Comments

0

0

• Datapoint